3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Interventions
fludarabine phosphate
58
Cyclophosphamide
54
Peripheral Blood Stem Cell Transplantation
49
Mycophenolic Acid
39
Busulfan
38
Tacrolimus
37
Cyclosporine
33
Antilymphocyte Serum
33
Whole-Body Irradiation
32
Filgrastim
28
Methotrexate
27
Radiotherapy
20
Melphalan
18
Cytarabine
17
fludarabine
16
Etoposide
16
Methylprednisolone
14
ruxolitinib
11
sargramostim
9
Flow Cytometry
9
Cyclosporins
9
Cord Blood Stem Cell Transplantation
9
Alemtuzumab
9
thymoglobulin
8
Sirolimus
8
Psychiatric Rehabilitation
8
Granulocyte Colony-Stimulating Factor
8
Azacitidine
8
merphos
7
Decitabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Myeloproliferative Disorders
×
anagrelide
×
Clear all
NCT02076815
2015-07-29
TEAM-ET
AOP Orphan Pharmaceuticals AG
Phase 3
Completed
106 enrolled